Background: Smoking, along with many respiratory diseases, has been shown to induce airway inflammation and alter the composition of the respiratory tract lining fluid (RTLF). We have previously shown that the phospholipid and protein composition of particles in exhaled air (PEx) reflects that of RTLF. In this study, we hypothesized that the composition of PEx differs between smokers and non-smokers, reflecting inflammation in the airways. Objective: It was the aim of this study to identify differences in the phospholipid composition of PEx from smokers and non-smokers. Methods: PEx from 12 smokers and 13 non-smokers was collected using a system developed in-house. PEx was analysed using time-of-flight secondary ion mass spectrometry, and the mass spectral data were evaluated using multivariate analysis. Orthogonal partial least squares (OPLS) was used to relate smoking status, lung function and pack years to the chemical composition of RTLF. The discriminating ions identified by OPLS were then used as explanatory variables in traditional regression analysis. Results: There was a clear discrimination between smokers and non-smokers according to the chemical composition, where phospholipids from smokers were protonated and sodiated to a larger extent. Poor lung function showed a strong association with higher response from all molecular phosphatidylcholine species in the samples. Furthermore, the accumulated amount of tobacco consumed was associated with variations in mass spectra, indicating a dose-response relationship. Conclusion: The chemical composition of PEx differs between smokers and non-smokers, reflecting differences in the RTLF. The results from this study may suggest that the composition of RTLF is affected by smoking and may be of importance for lung function.

Keywords:
Cigarette smoking, Inflammation, Orthogonal partial least squares, Particles in exhaled air, Phospholipids, Respiratory tract lining fluid, Time-of-flight secondary ion mass spectrometry
1.
Maestrelli P, Saetta M, Mapp CE, Fabbri LM: Remodeling in response to infection and injury. Airway inflammation and hypersecretion of mucus in smoking subjects with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:76-80.
2.
Adcock IM, Caramori G, Barnes PJ: Chronic obstructive pulmonary disease and lung cancer: new molecular insights. Respiration 2011;81:265-284.
3.
Goerke J: Lung surfactant. Biochim Biophys Acta 1974;344:241-261.
4.
Heeley EL, Hohlfeld JM, Krug N, Postle AD: Phospholipid molecular species of bronchoalveolar lavage fluid after local allergen challenge in asthma. Am J Physiol Lung Cell Mol Physiol 2000;278:L305-L311.
5.
Mander A, Langton-Hewer S, Bernhard W, Warner JO, Postle AD: Altered phospholipid composition and aggregate structure of lung surfactant is associated with impaired lung function in young children with respiratory infections. Am J Respir Cell Mol Biol 2002;27:714-721.
6.
Wright SM, Hockey PM, Enhorning G, Strong P, Reid KB, Holgate ST, et al: Altered airway surfactant phospholipid composition and reduced lung function in asthma. J Appl Physiol 2000;89:1283-1292.
7.
Isajevs S, Taivans I, Svirina D, Strazda G, Kopeika U: Patterns of inflammatory responses in large and small airways in smokers with and without chronic obstructive pulmonary disease. Respiration 2011;81:362-371.
8.
Hughes DA, Haslam PL: Effect of smoking on the lipid composition of lung lining fluid and relationship between immunostimulatory lipids, inflammatory cells and foamy macrophages in extrinsic allergic alveolitis. Eur Respir J 1990;3:1128-1139.
9.
Plymoth A, Löfdahl CG, Ekberg-Jansson A, Dahlback M, Broberg P, Foster M, et al: Protein expression patterns associated with progression of chronic obstructive pulmonary disease in bronchoalveolar lavage of smokers. Clin Chem 2007;53:636-644.
10.
More J, Voelker D, Silveira L, Edwards M, Chan E, Bowler R: Smoking reduces surfactant protein D and phospholipids in patients with and without chronic obstructive pulmonary disease. BMC Pulm Med 2010;10:53.
11.
Almstrand A-C, Ljungström E, Lausmaa J, Bake B, Sjövall P, Olin A-C: Airway monitoring by collection and mass spectrometric analysis of exhaled particles. Anal Chem 2008;81:662-668.
12.
Almstrand AC, Bake B, Ljungström E, Larsson P, Bredberg A, Mirgorodskaya E, et al: Effect of airway opening on production of exhaled particles. J Appl Physiol 2010;108:584-588.
13.
Bredberg A, Gobom J, Almstrand AC, Larsson P, Blennow K, Olin AC, et al: Exhaled endogenous particles contain lung proteins. Clin Chem 2012;58:431-440.
14.
Benninghoven A: Surface analysis by Secondary Ion Mass Spectrometry (SIMS). Surf Sci 1994;299/300:246-260.
15.
Saleem M, Galla H-J: Surface view of the lateral organization of lipids and proteins in lung surfactant model systems - a ToF-SIMS approach. Biochim Biophys Acta 2010;1798:730-740.
16.
Graham DJ, Wagner MS, Castner DG: Information from complexity: challenges of TOF-SIMS data interpretation. Appl Surf Sci 2006;252:6860-6868.
17.
Berman ESF, Wu L, Fortson SL, Kulp KS, Nelson DO, Wu KJ: Chemometric and statistical analyses of ToF-SIMS spectra of increasingly complex biological samples. Surf Interface Anal 2009;41:97-104.
18.
Tyler BJ, Rayal G, Castner DG: Multivariate analysis strategies for processing ToF-SIMS images of biomaterials. Biomaterials 2007;28:2412-2423.
19.
Wagner MS, Graham DJ, Castner DG: Simplifying the interpretation of ToF-SIMS spectra and images using careful application of multivariate analysis. Appl Surf Sci 2006;252:6575-6581.
20.
Trygg J, Wold S: Orthogonal projections to latent structures (O-PLS). J Chemom 2002;16:119-128.
21.
American Thoracic Society, European Respiratory Society: ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005;171:912-930.
22.
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al: Standardisation of spirometry. Eur Respir J 2005;26:319-338.
23.
Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC: Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:5-40.
24.
Trygg J, Holmes E, Lundstedt T: Chemometrics in metabonomics. J Proteome Res 2006;6:469-479.
25.
van den Berg RA, Hoefsloot HC, Westerhuis JA, Smilde AK, van der Werf MJ: Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genomics 2006;7:142.
26.
Bylesjö M, Rantalainen M, Cloarec O, Nicholson JK, Holmes E, Trygg J: OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification. J Chemom 2006;20:341-351.
27.
Wiklund S, Johansson E, Sjöstrom L, Mellerowicz EJ, Edlund U, Shockcor JP, et al: Visualization of GC/TOF-MS-based metabolomics data for identification of biochemically interesting compounds using OPLS class models. Anal Chem 2008;80:115-122.
28.
Almstrand A-C, Josefson M, Bredberg A, Lausmaa J, Sjövall P, Larsson P, et al: TOF-SIMS analysis of exhaled particles from patients with asthma and healthy controls. Eur Respir J 2012;39:59-66.
29.
Belu AM, Graham DJ, Castner DG: Time-of-flight secondary ion mass spectrometry: techniques and applications for the characterization of biomaterial surfaces. Biomaterials 2003;24:3635-3653.
30.
Hu S, Xie Y, Ramachandran P, Ogorzalek Loo RR, Li Y, Loo JA, et al: Large-scale identification of proteins in human salivary proteome by liquid chromatography/mass spectrometry and two-dimensional gel electrophoresis-mass spectrometry. Proteomics 2005;5:1714-1728.
31.
Seasholtz MB, Kowalski BR: Qualitative information from multivariate calibration models. Appl Spectrosc 1990;44:1337-1348.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.